You won't want to miss out on the world-class speakers at TNW Conference this year 🎟 Book your 2 for 1 tickets now! This offer ends on April 22 →

This article was published on February 23, 2024

This startup is bioengineering tissue into human vein implants

Clexbio believes bioengineering will create a "paradigm shift" in healthcare

This startup is bioengineering tissue into human vein implants

Norwegian startup ClexBio is bioengineering human veins to implant inside a patient’s body.

Together with CSEM, a Swiss R&D centre, the company has built a prototype bioreactor to grow the veins.

Pre-clinical tests in animal models are already underway. Based on the early results, the team is confident that the implants don’t trigger an immune response in patients. Instead, they turn into functional tissue that integrates with the body.

If further tests prove successful, the implants could treat severe chronic venous insufficiency, a painful condition caused when veins have problems moving blood to the heart.

But veins are just the start of the company’s ambitions. ClexBio envisions bioengineering producing various medical treatments.

The <3 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!

“In the future, we believe tissue therapeutic solutions will provide a cure for many of the chronic conditions that are debilitating for our society today,” Armend Håti, the startup’s CEO and co-founder, told TNW.

Bioengineering body parts

A series of bioreactors for bioengineering vein grafts, developed by CSEM and ClexBio
The new tech aims to scale bioengineering. Credit: ClexBio

At the core of ClexBio’s tech is the VivoSet platform, which can cultivate tissues into real human anatomies, such as veins.

To produce them in a scalable fashion, the startup developed the bioreactor.

Inside the machine, the veins mature over a few weeks in a sterile environment. Automated media circulation provides the tissue with oxygen and nutrients.

“Using a closed system to generate the vein grafts reduces the risk of contamination, ensures product quality and safety, and facilitates regulatory compliance,” Håti said.

“This is a vital prerequisite for our ability to conduct in-human studies and scale up commercially in a GMP [Good Manufacturing Practices] setting in the future.” 

As the veins mature, the system forms them into a graft. ClexBio said they can then be implanted into patients “off the shelf.”

Before that happens, the tech will have to pass an array of tests and clear regulatory reviews. But Håti is already imagining the real-world impact.

“We are truly excited about the paradigm shift this may usher in for human surgery and the treatment of damaged tissues,” he said.

“We are moving away from a world of synthetic implants and stepping into the world of bioengineering.”

Get the TNW newsletter

Get the most important tech news in your inbox each week.

Also tagged with

Back to top